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G
TSsophageal adenocarcinoma cells. During our immunostain-
ng, we encountered isolated instances of positive csPCNA
taining in histologically nonmalignant tissue. The staining
attern in these cases differed slightly between tissue ob-
ained by formal resection and tissue obtained by endo-
copic biopsy, indicating a possible effect of tissue prepa-
ation on the specificity of csPCNA detection. Although
uch staining of nonmalignant tissue may indicate nonspe-
ific staining by the csPCNAab, other possibilities include
he detection of early malignant changes in histologically
onmalignant-appearing cells as well as an effect of tissue
reparation, such as the amount of hypoxic time, on alter-
tions of PCNA. These issues are currently the focus of
urther investigations into the specificity of the csPCNAab
cross many tissue types. It should be emphasized, however,
hat the detection of csPCNA in nonmalignant tissue has
een limited, whereas all malignant tissues have stained
ositively for csPCNA.
Taken together, these preliminary studies suggest that
sPCNA may be a marker for esophageal adenocarcinoma.
f confirmed by future studies, this finding would have great
mplications for the treatment of patients with cancer. By
sing the csPCNAab to follow the status of csPCNA, it may
e possible to monitor the response of individual patients to
eoadjuvant chemoradiation, with the lack of detection sig-
ifying a pathologically complete response. If this tech-
ique is proved reliable for the detection of pathologically
omplete response, it may then be possible to perform a trial
omparing the outcomes of patients with pathologically
omplete response with and without surgery. It may also be
ossible to diagnose cancer at an early stage, concealed
ithin high-grade dysplasia. The csPCNAab may become a
seful member of a panel of antibodies that have the ability
o recognize markers currently used to evaluate tumors for
heir malignant potential, yielding a prognosis. Finally, the
sPCNAab may be a useful reagent for developing enzyme-
inked immunosorbent assays and immunohistochemical as-
ays for screening purposes.
eferences
. Devasa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence
of esophageal and gastric carcinoma in the United States. Cancer.
1998;83:2049-53.
. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends
Genet. 1993;9:138-41.
. Sekowski JW, Malkas LH, Schnaper L, Bechtel PE, Long BJ, Hickey
RJ. Human breast cancer cells contain an error prone DNA replication
apparatus. Cancer Res. 1998;58:3259-63.
. Hickey RJ, Malkas LH. Mammalian cell DNA replication. Crit Rev
Eukaryot Gene Expr. 1997;7:125-57.
. Malkas LH, Bechtel PE, Sekowski JW, Schnaper L, Lankford CR,
Hoelz DJ, et al. A cancer-specific form of proliferating cell nuclear
antigen (csPCNA) is present in malignant human breast cells and
tissues. J Clin Ligand Assay. 2002;25:20-32.. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H.
The prognostic significance of proliferating cell nuclear antigen, epi- l
6 The Journal of Thoracic and Cardiovascular Surgery ● Januadermal growth factor receptor, and mdr gene expression in colorectal
cancer. Cancer. 1993;71:2454-60.
. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE,
et al. Proliferating cell nuclear antigen (PCNA) immunostaining—a
prognostic factor in ovarian cancer? Br J Cancer. 1995;71:357-62.
. Jain S, Filipe MI, Hall PA, Waseem N, Lane DP, Levison DA. Prog-
nostic value of proliferating cell nuclear antigen in gastric carcinoma.
J Clin Pathol. 1991;44:655-9.
. Bechtel PE, Hickey RJ, Schnaper L, Sekowski JW, Long BJ, Freund R,
et al. A unique form of proliferating cell nuclear antigen is present in
malignant breast cells. Cancer Res. 1998;58:3264-9.
iscussion
r Michael Weyant (Denver, Colo). Dr Hammoud, congratula-
ions on your article. I enjoyed reading it, and I appreciate you
ending it to me well ahead of the date of this meeting.
You and your coauthors have found a unique biomarker iden-
ifying and isolating malignant cells in esophageal tissue. I think
ndings such as these are important not only because of the ability
o mark a cell but also because they can eventually provide some
nsight into the biology of the cancer cell itself. You also were able
o show us a method that is applicable immediately globally to all
athologists, and I think that is important. But I have a few
uestions for you.
First, given that a pathologist on a routine hematoxylin and
osin stain can identify a cancer cell on the basis of its nuclear
orphology, and you have basically to have the presence of the
ancer cell to identify it, how is your technique an actual improve-
ent over those already known methods?
Dr Hammoud. I alluded to this earlier. I think a lot of times the
ifferentiation between high-grade dysplasia and invasive carci-
oma is difficult and is pathologist dependent. I think the greatest
tility right now of having this antibody is in exactly those sce-
arios. I agree wholeheartedly that you don’t need this antibody to
iagnose cancer, at least not on a biopsy or a tissue specimen, but
think in those difficult cases it can help. I foresee this as basically
eing a member of a panel of antibodies that we might be able to
se to form some prognostic indicators or, as I said, for those cases
here one cannot differentiate high-grade dysplasia from invasive
ancer. I think the really exciting potential, however, is the ability
o diagnose or pick up csPCNA in the serum. I think that’s where
he money is, and that’s where the biggest clinical impact is
otentially going to be.
Dr Weyant. For my second question, and you alluded to this in
our article, one of the important applications I see is in looking at
roups of patients who have been treated and determining the level
f treatment response. We have a group of patients who are
etermined to have complete response on the basis of pathologic
nalysis, and they are thought to have a better prognosis. Yet they
on’t survive forever. I think that with your technique we can
tratify groups of these patients. Because these tissues came from
our tissue bank at the university, have you had the opportunity to
valuate those patients and their responses to their specific treat-
ents?
Dr Hammoud. The short answer is no; however, we have an
nstitutional Review Board–approved prospective study underway
ight now. As at many other institutions, most of our patients,
robably 90%, are getting neoadjuvant chemoradiation. Our pro-
ocol attempts to predict which patients have a complete patho-
ogic response. At restaging endoscopic ultrasonography after the
ry 2007
ce
t
s
l
c
f
c
t
l
w
y
w
w
w
h
w
t
t
p
p
t
b
i
t
i
T
i
e
l
s
l
a
a
t
m
t
a
a
w
h
p
t
d
t
i
g
g
b
d
g
c
t
t
f
g
s
d
t
a
c
Hammoud et al General Thoracic Surgery
G
TSompletion of neoadjuvant therapy, if no visible tumor is seen, the
ndoscopist will perform four quadrant biopsies in the area where
he tumor had been seen before treatment. Patients go on to
urgical resection, and if in fact they have had a complete patho-
ogic response we can go back and take a look and see whether we
ould have predicted that complete pathologic response by staining
or csPCNA. As you know, 25% to 30% of patients will have a
omplete pathologic response after their neoadjuvant therapy, and
he only way to know that is to take the esophagus out. We would
ike to see whether by using this antibody we can reliably predict
hich patient has had a complete pathologic response.
Dr Weyant. Great work. Thank you very much.
Dr Hammoud. Thank you.
Dr Donald Low (Seattle, Wash). Once again, I congratulate
ou on your work. It is potentially another step in the modalities
e are all going to be using to determine which patients require
hat types of treatment. To that end, specifically, one of the issues
e’re all dealing with right now is that for patients we believe to
ave true high-grade dysplasia or even intramucosal cancer, we’re
eighing with risks and benefits of endoscopic versus surgical
herapy. One of the things that comes to mind regarding your
echnique is the ability to increase accuracy of interpretation of the
resence or absence of cancer cells up to or through the lamina
ropria. Have you begun to use this type of technology to increase
he acuity of this assessment in presurgical patients, so that we can
egin to apply the endoscopic modalities more appropriately?
Dr Hammoud. No, but that is obviously the goal. As I stated
n my comments, this is a work in progress. The first goal is for us
o try to make a monoclonal antibody. We know from antibodies
n general that monoclonals tend to be better than polyclonals.
hey are certainly easier to work with in terms of developing
mmunohistochemical conditions, but I agree with you. That is
xactly where the clinical applicabilities of this type of antibody
ie, and that is where the future is. We also struggle with—and I’m
ure a lot of people in this room have similar experiences to us—a m
The Journal of Thoracot of the T1 cases not making it to us. They are just being treated,
nd it’s not right, but it happens. It happens in the communities,
nd it happens at our university even though we beg and plead and
ell everybody that these things need to be handled in a true
ultidisciplinary fashion, but that’s the reality. We just talked in
he previous discussion about how lung cancers get treated without
ny of our input. A lot of these T1 and high-grade dysplasia cases
re being treated without our input, and needless to say somebody
ho does that generally doesn’t know about this technology or
ow they can potentially improve patient outcome.
Dr Richard Whyte (Stanford, Calif), Thanks for an interesting
resentation. One of the comments you made, or suggested, was
hat the problem of separating invasive carcinoma from high-grade
ysplasia was related to the pathologist reading the slide. I think
hat this particular issue is more a sampling issue, whereas an
nterpretative or pathologist-specific issue is distinguishing low-
rade from high-grade dysplasia, where as you know there is a
reat deal of interobserver variability.
My question to you, though, has to do with the role of this
iomarker in either screening patients with Barrett esophagus or
iscriminating patients with progression from low-grade to high-
rade dysplasia or from high-grade dysplasia to invasive adeno-
arcinoma. Do you have any data on cytologic analysis with this
echnique?
Dr Hammoud. No. This marker is really present in malignant
issue. The only thing we’ve shown thus far is its presence in
rankly malignant tissue. In both low-grade dysplasia and high-
rade dysplasia, none of specimens was stained by this antibody,
o it would not be helpful in that regard. Whether we can show
ifferences between high- and low-grade dysplasias is something
hat I’m working on right now with serum proteomics. I’m looking
t normal tissue, low-grade dysplasia, high-grade dysplasia, and
ancers and trying to determine protein patterns in serum that
ight help us spot that progression.
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